330 related articles for article (PubMed ID: 30983996)
1. Biological Therapies in Immune-Mediated Inflammatory Diseases: Can Biosimilars Reduce Access Inequities?
Baumgart DC; Misery L; Naeyaert S; Taylor PC
Front Pharmacol; 2019; 10():279. PubMed ID: 30983996
[TBL] [Abstract][Full Text] [Related]
2. The Impact of Inflammatory Bowel Disease in Canada 2018: Direct Costs and Health Services Utilization.
Kuenzig ME; Benchimol EI; Lee L; Targownik LE; Singh H; Kaplan GG; Bernstein CN; Bitton A; Nguyen GC; Lee K; Cooke-Lauder J; Murthy SK
J Can Assoc Gastroenterol; 2019 Feb; 2(Suppl 1):S17-S33. PubMed ID: 31294382
[TBL] [Abstract][Full Text] [Related]
3. Biosimilars and access to biologic therapy in immune-mediated diseases.
Vázquez-Sánchez R; Navarro-Dávila M; Herráiz ER; Merino-Bohórquez V; Borrás-Blasco J; Onteniente-González A; Iglesias-Lambarri A; Negro-Vega E
Expert Opin Biol Ther; 2024 May; ():1-7. PubMed ID: 38698351
[TBL] [Abstract][Full Text] [Related]
4. Biosimilars in immune-mediated inflammatory diseases: initial lessons from the first approved biosimilar anti-tumour necrosis factor monoclonal antibody.
Isaacs JD; Cutolo M; Keystone EC; Park W; Braun J
J Intern Med; 2016 Jan; 279(1):41-59. PubMed ID: 26403380
[TBL] [Abstract][Full Text] [Related]
5. Adoption of Biosimilar Infliximab for Rheumatoid Arthritis, Ankylosing Spondylitis, and Inflammatory Bowel Diseases in the EU5: A Budget Impact Analysis Using a Delphi Panel.
Kanters TA; Stevanovic J; Huys I; Vulto AG; Simoens S
Front Pharmacol; 2017; 8():322. PubMed ID: 28620302
[No Abstract] [Full Text] [Related]
6. The Future of Biosimilars: Maximizing Benefits Across Immune-Mediated Inflammatory Diseases.
Kim H; Alten R; Avedano L; Dignass A; Gomollón F; Greveson K; Halfvarson J; Irving PM; Jahnsen J; Lakatos PL; Lee J; Makri S; Parker B; Peyrin-Biroulet L; Schreiber S; Simoens S; Westhovens R; Danese S; Jeong JH
Drugs; 2020 Feb; 80(2):99-113. PubMed ID: 32002851
[TBL] [Abstract][Full Text] [Related]
7. Regulatory aspects of biological medicines in Bosnia and Herzegovina.
Tubić B; Jungić S
Bosn J Basic Med Sci; 2022 Jul; 22(4):511-522. PubMed ID: 35460398
[TBL] [Abstract][Full Text] [Related]
8. [Biosimilars: opportunities and risks].
Grieshaber-Bouyer R; Lorenz HM
Internist (Berl); 2020 May; 61(5):522-529. PubMed ID: 32333085
[TBL] [Abstract][Full Text] [Related]
9. A place for biosimilars in the changing multiple sclerosis treatment landscape.
Greenberg B; Giovannoni G
Mult Scler Relat Disord; 2023 Sep; 77():104841. PubMed ID: 37467536
[TBL] [Abstract][Full Text] [Related]
10. The Economic Impact of Biosimilars on Chronic Immune-Mediated Inflammatory Diseases.
Pentek M; Zrubka Z; Gulacsi L
Curr Pharm Des; 2017; 23(44):6770-6778. PubMed ID: 29189134
[TBL] [Abstract][Full Text] [Related]
11. Identifying Key Benefits in European Off-Patent Biologics and Biosimilar Markets: It is Not Only About Price!
Dutta B; Huys I; Vulto AG; Simoens S
BioDrugs; 2020 Apr; 34(2):159-170. PubMed ID: 31792843
[TBL] [Abstract][Full Text] [Related]
12. Biosimilars of Adalimumab in Inflammatory Bowel Disease: Are we Ready for that?
Argollo M; Fiorino G; Gilardi D; Furfaro F; Roda G; Loy L; Allocca M; Peyrin-Biroulet L; Danese S
Curr Pharm Des; 2019; 25(1):7-12. PubMed ID: 30864505
[TBL] [Abstract][Full Text] [Related]
13. Biosimilar Drugs for Psoriasis: Principles, Present, and Near Future.
Carrascosa JM; Jacobs I; Petersel D; Strohal R
Dermatol Ther (Heidelb); 2018 Jun; 8(2):173-194. PubMed ID: 29549597
[TBL] [Abstract][Full Text] [Related]
14. Clinical and regulatory perspectives on biosimilar therapies and intended copies of biologics in rheumatology.
Mysler E; Pineda C; Horiuchi T; Singh E; Mahgoub E; Coindreau J; Jacobs I
Rheumatol Int; 2016 May; 36(5):613-25. PubMed ID: 26920148
[TBL] [Abstract][Full Text] [Related]
15. Comparative Price Analysis of Biological Products for Treatment of Rheumatoid Arthritis.
Manova M; Savova A; Vasileva M; Terezova S; Kamusheva M; Grekova D; Petkova V; Petrova G
Front Pharmacol; 2018; 9():1070. PubMed ID: 30294275
[TBL] [Abstract][Full Text] [Related]
16. Biosimilars for the management of rheumatoid arthritis: economic considerations.
Gulácsi L; Brodszky V; Baji P; Kim H; Kim SY; Cho YY; Péntek M
Expert Rev Clin Immunol; 2015; 11 Suppl 1():S43-52. PubMed ID: 26395836
[TBL] [Abstract][Full Text] [Related]
17. Safety of Biologics, Including Biosimilars: Perspectives on Current Status and Future Direction.
Ingrasciotta Y; Cutroneo PM; Marcianò I; Giezen T; Atzeni F; Trifirò G
Drug Saf; 2018 Nov; 41(11):1013-1022. PubMed ID: 29796832
[TBL] [Abstract][Full Text] [Related]
18. Policies for biosimilar uptake in Europe: An overview.
Moorkens E; Vulto AG; Huys I; Dylst P; Godman B; Keuerleber S; Claus B; Dimitrova M; Petrova G; Sović-Brkičić L; Slabý J; Šebesta R; Laius O; Karr A; Beck M; Martikainen JE; Selke GW; Spillane S; McCullagh L; Trifirò G; Vella Bonanno P; Mack A; Fogele A; Viksna A; Władysiuk M; Mota-Filipe H; Meshkov D; Kalaba M; Mencej Bedrač S; Fürst J; Zara C; Skiöld P; Magnússon E; Simoens S
PLoS One; 2017; 12(12):e0190147. PubMed ID: 29284064
[TBL] [Abstract][Full Text] [Related]
19. Biosimilars: Review of current applications, obstacles, and their future in medicine.
Kaida-Yip F; Deshpande K; Saran T; Vyas D
World J Clin Cases; 2018 Aug; 6(8):161-166. PubMed ID: 30148143
[TBL] [Abstract][Full Text] [Related]
20. [The Polish Task Force position statement on safety of biologic treatment with monoclonal antibodies and soluble receptors].
Jahnz-Rozyk K; Wiesik-Szewczyk E;
Pol Merkur Lekarski; 2014 Jul; 37(217):5-9. PubMed ID: 25154192
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
